LGND

LIGAND PHARMACEUTICALS INC

LGND · CIK 886163 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$268M
20182025
Net Income$124M
20182025
Operating CF$49M
20182025
Free Cash Flow$49M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.3B$0.2B$0.1B$0.1B$0.3B$0.1B$0.0B$0.1B
Cost of Revenue———————$0.0B
Gross Profit————————
R&D Expense$0.1B$0.0B$0.0B$0.0B$0.1B$0.1B$0.1B$0.0B
SG&A Expense————————
Operating Income$0.0B$-0.0B$0.0B$0.0B$0.1B$0.0B$0.8B$0.2B
Net Income$0.1B$-0.0B$0.1B$-0.0B$0.1B$0.0B$-0.0B$-0.0B
EPS (Basic)$6.44$-0.22$3.02$-1.98$3.44$0.36$-0.43$-0.33
EPS (Diluted)$6.13$-0.22$2.94$-1.98$3.31$0.35$-0.43$-0.33

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.6B$0.9B$0.8B$0.8B$1.3B$1.4B$1.5B$1.3B
Current Assets$0.8B$0.3B$0.2B$0.3B$0.5B$0.5B$1.1B$0.9B
Cash & Equivalents$0.2B$0.1B$0.0B$0.0B$0.0B$0.0B$0.1B$0.1B
Total Liabilities$0.5B$0.1B$0.1B$0.2B$0.5B$0.7B$0.7B$0.7B
Current Liabilities$0.0B$0.0B$0.0B$0.1B$0.0B$0.1B$0.0B$0.1B
Stockholders' Equity$1.0B$0.8B$0.7B$0.6B$0.8B$0.7B$0.8B$0.6B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$0.0B$0.1B$0.0B$0.1B$0.1B$0.1B$-0.0B$0.2B
Investing Cash Flow$-0.4B$-0.1B$-0.0B$0.2B$0.0B$0.2B$0.5B$-0.4B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.4B$0.1B$-0.1B$-0.3B$-0.1B$-0.3B$-0.5B$0.3B
← Companies